Esperion has recalled approximately 3,480 30-count bottles of Nexlizet (bempedoic acid and ezetimibe) tablets (180 mg/10 mg). The recall was issued because the medication failed bempedoic acid dissolution tests at its initial testing point, meaning the drug may not dissolve properly in the body. This could potentially reduce the medication's effectiveness in managing cholesterol levels.
The medication failed to meet dissolution specifications, which may prevent the active ingredients from being absorbed correctly by the body. No incidents or injuries have been reported to date.
You have 2 options:
Recall #: D-0441-2024
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.